Apollon Formularies (AQSE:APOL) COGS-to-Revenue : 0.00 (As of Jun. 2023)

View and export this data going back to . Start your Free Trial

What is Apollon Formularies COGS-to-Revenue?

Apollon Formularies's Cost of Goods Sold for the six months ended in Jun. 2023 was £0.00 Mil. Its Revenue for the six months ended in Jun. 2023 was £0.05 Mil.

Apollon Formularies's COGS to Revenue for the six months ended in Jun. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Apollon Formularies's Gross Margin % for the six months ended in Jun. 2023 was N/A%.

Apollon Formularies COGS-to-Revenue Historical Data

The historical data trend for Apollon Formularies's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies COGS-to-Revenue Chart

Apollon Formularies Annual Data

Trend

Jun10

Jun11

Dec12

Dec13

Dec14

Dec17

Dec18

Dec19

Dec20

Dec21

COGS-to-Revenue

Get a 7-Day Free Trial

0.91

0.97

Apollon Formularies Semi-Annual Data
	Jun11	Jun12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Jun23
COGS-to-Revenue	Get a 7-Day Free Trial											-	-	-	-	-

Apollon Formularies COGS-to-Revenue Calculation

Apollon Formularies's COGS to Revenue for the fiscal year that ended in Dec. 2021 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0.198
	=	0.00

Apollon Formularies's COGS to Revenue for the quarter that ended in Jun. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0.048
	=	0.00

Apollon Formularies (AQSE:APOL) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Apollon Formularies's Gross Margin % for the six months ended in Jun. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0.048
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Apollon Formularies COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Apollon Formularies (AQSE:APOL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS

Website

https://www.apollon.org.uk

Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.